Matt Zuga - Net Worth and Insider Trading

Matt Zuga Net Worth

The estimated net worth of Matt Zuga is at least $2 Million dollars as of 2024-12-28. Matt Zuga is the Director of TELA Bio Inc and owns about 514,481 shares of TELA Bio Inc (TELA) stock worth over $1 Million. Matt Zuga is also the CFO & Chief Business Officer of Acumen Pharmaceuticals Inc and owns about 211,445 shares of Acumen Pharmaceuticals Inc (ABOS) stock worth over $376,372. Details can be seen in Matt Zuga's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Matt Zuga has not made any transactions after 2024-01-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Matt Zuga

To

Matt Zuga Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Matt Zuga owns 5 companies in total, including Elutia Inc (ELUT) , HighCape Capital Acquisition Corp (CAPAU) , and TELA Bio Inc (TELA) among others .

Click here to see the complete history of Matt Zuga’s form 4 insider trades.

Insider Ownership Summary of Matt Zuga

Ticker Comapny Transaction Date Type of Owner
ELUT Elutia Inc 2020-10-07 director & 10 percent owner
CAPAU HighCape Capital Acquisition Corp 2020-09-03 director & 10 percent owner
TELA TELA Bio Inc 2019-11-08 director
LIMIT LIMIT 2024-01-18 Chief Financial Officer
LIMIT LIMIT 2020-09-03 director & 10 percent owner

Matt Zuga Latest Holdings Summary

Matt Zuga currently owns a total of 2 stocks. Among these stocks, Matt Zuga owns 514,481 shares of TELA Bio Inc (TELA) as of November 8, 2019, with a value of $1 Million and a weighting of 79.91%. Matt Zuga also owns 211,445 shares of Acumen Pharmaceuticals Inc (ABOS) as of January 18, 2024, with a value of $376,372 and a weighting of 20.09%.

Latest Holdings of Matt Zuga

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TELA TELA Bio Inc 2019-11-08 514,481 2.91 1,497,140
ABOS Acumen Pharmaceuticals Inc 2024-01-18 211,445 1.78 376,372

Holding Weightings of Matt Zuga


Matt Zuga Form 4 Trading Tracker

According to the SEC Form 4 filings, Matt Zuga has made a total of 0 transactions in TELA Bio Inc (TELA) over the past 5 years. The most-recent trade in TELA Bio Inc is the acquisition of 86,121 shares on November 8, 2019, which cost Matt Zuga around $1 Million.

According to the SEC Form 4 filings, Matt Zuga has made a total of 1 transactions in Acumen Pharmaceuticals Inc (ABOS) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Acumen Pharmaceuticals Inc is the sale of 4,242 shares on January 18, 2024, which brought Matt Zuga around $15,738.

Insider Trading History of Matt Zuga

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Matt Zuga Trading Performance

GuruFocus tracks the stock performance after each of Matt Zuga's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Matt Zuga is 14.23%. GuruFocus also compares Matt Zuga's trading performance to market benchmark return within the same time period. The performance of stocks bought by Matt Zuga within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Matt Zuga's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Matt Zuga

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -7.34 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -9.05 LIMIT LIMIT LIMIT LIMIT LIMIT

Matt Zuga Ownership Network

Ownership Network List of Matt Zuga

No Data

Ownership Network Relation of Matt Zuga

Insider Network Chart

Matt Zuga Owned Company Details

What does Elutia Inc do?

Who are the key executives at Elutia Inc?

Matt Zuga is the director & 10 percent owner of Elutia Inc. Other key executives at Elutia Inc include 10 percent owner Elutia Pipe Investment, Lp , 10 percent owner Birchview Fund Llc , and Chief Commercial Officer Thomas Englese .

Elutia Inc (ELUT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Elutia Inc (ELUT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Elutia Inc (ELUT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Elutia Inc (ELUT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Elutia Inc Insider Transactions

No Available Data

Matt Zuga Mailing Address

Above is the net worth, insider trading, and ownership report for Matt Zuga. You might contact Matt Zuga via mailing address: C/o Tela Bio, Inc., 1 Great Valley Parkway, Suite 24, Malvern Pa 19355.

Discussions on Matt Zuga

No discussions yet.